Literature DB >> 33472642

miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways.

Yang Li1, Xiaotao Long1, Ji Wang1, Jing Peng1, Kai Shen2.   

Abstract

BACKGROUND: Bone neoplasms present poor prognosis due to recurrence and metastasis. Although the role microRNAs (miRNAs) in inhibiting growth and metastasis of bone neoplasms has been investigated, the underlying potential molecular mechanisms mediated by miRNA-128 (miR-218) for the invasiveness of bone neoplasms cells are still not completely understood. The purpose of this study was to identify the regulatory mechanisms of miR-218 in bone neoplasms cells.
METHODS: Western blotting, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Counting Kit-8 assay, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining, luciferase activity assay immunofluorescence, and immunohistochemistry were used to analyze the regulatory effects of miR-218 on bone neoplasms cells.
RESULTS: Here, the results showed that transfection of miR-128 suppressed bone neoplasms cells proliferation, migration, and invasion. Genetic knockdown of miR-128 in bone neoplasms cells suppressed the activation of the Wnt/β-catenin and epithelial-mesenchymal transition (EMT) signaling pathways. Activation of Wnt or EMT blocked miR-128-inhibited cells proliferation and migration in bone neoplasms cells. Exogenously introduced miR-128 markedly inhibited tumor regeneration in bone neoplasms xenograft models.
CONCLUSIONS: These results define a tumor-regulated function for miR-128 in bone neoplasms by down-regulation of the Wnt/β-catenin and EMT signal pathways, which provided a potential target for bone neoplasms gene therapy.

Entities:  

Keywords:  Bone neoplasms; EMT; Migration; Proliferation; Wnt/β-catenin; miRNA-128

Mesh:

Substances:

Year:  2021        PMID: 33472642      PMCID: PMC7816476          DOI: 10.1186/s13018-020-02164-w

Source DB:  PubMed          Journal:  J Orthop Surg Res        ISSN: 1749-799X            Impact factor:   2.359


  39 in total

Review 1.  Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

Authors:  Y Loriot; C Massard; K Fizazi
Journal:  Ann Oncol       Date:  2012-01-20       Impact factor: 32.976

2.  Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis.

Authors:  Lei Wang; Gui-Bin Xue
Journal:  Biochem Biophys Res Commun       Date:  2017-10-12       Impact factor: 3.575

Review 3.  A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.

Authors:  A F Leger; M Pellan; F Dagousset; A Chevalier; I Keller; J Clerc
Journal:  Br J Radiol       Date:  2005-05       Impact factor: 3.039

4.  Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.

Authors:  Sebastian Fernandez-Pol; Lisa Ma; Robert S Ohgami; Daniel A Arber
Journal:  Mod Pathol       Date:  2016-12-09       Impact factor: 7.842

5.  SENP1/HIF-1α feedback loop modulates hypoxia-induced cell proliferation, invasion, and EMT in human osteosarcoma cells.

Authors:  Xiaowei Wang; Xiaoju Liang; Huan Liang; Bing Wang
Journal:  J Cell Biochem       Date:  2017-09-27       Impact factor: 4.429

Review 6.  Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.

Authors:  Celestia S Higano
Journal:  Urol Clin North Am       Date:  2004-05       Impact factor: 2.241

7.  Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis.

Authors:  Brian Ell; Laura Mercatali; Toni Ibrahim; Neil Campbell; Heidi Schwarzenbach; Klaus Pantel; Dino Amadori; Yibin Kang
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

8.  Bone-Cancer Assessment and Destruction Pattern Analysis in Long-Bone X-ray Image.

Authors:  Oishila Bandyopadhyay; Arindam Biswas; Bhargab B Bhattacharya
Journal:  J Digit Imaging       Date:  2019-04       Impact factor: 4.056

9.  Prognostic value of C-reactive protein levels in patients with bone neoplasms: A meta-analysis.

Authors:  Wenyi Li; Xujun Luo; Zhongyue Liu; Yanqiao Chen; Zhihong Li
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

10.  miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38.

Authors:  Xue Liang; Wenfeng Shangguan; Miaomiao Zhang; Shiyue Mei; Liyang Wang; Rongcun Yang
Journal:  Mol Med Rep       Date:  2017-06-07       Impact factor: 2.952

View more
  3 in total

Review 1.  Newly Released Advances in the Molecular Mechanisms of Osseous Metastasis and Potential Therapeutic Strategies.

Authors:  E Carlos Rodriguez-Merchan; Manuel Peleteiro-Pensado
Journal:  Arch Bone Jt Surg       Date:  2022-09

2.  Tumor Cell-Derived Exosomal miR-770 Inhibits M2 Macrophage Polarization via Targeting MAP3K1 to Inhibit the Invasion of Non-small Cell Lung Cancer Cells.

Authors:  Jixian Liu; Ruixing Luo; Junbin Wang; Xinyu Luan; Da Wu; Hua Chen; Qinghua Hou; Guangxian Mao; Xiaoqiang Li
Journal:  Front Cell Dev Biol       Date:  2021-06-14

3.  lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell.

Authors:  Yongye Huang; Ziyan Zhou; Jin Zhang; Zhenzhen Hao; Yunhao He; Zihan Wu; Yiquan Song; Kexun Yuan; Shanyu Zheng; Qi Zhao; Tianye Li; Bing Wang
Journal:  J Cell Mol Med       Date:  2021-06-24       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.